prothymosin alpha raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-20 and is reviewed periodically as new material appears.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
==== Viñas Alonso expelled from the Grand Lodge ==== On February 19, the Second Chamber of the Supreme Court of Masonic Justice heard the case of Viñas Alonso that had been referred to them by Grand Master Urquía Carreño. The President of the Second Chamber, Zamir Brindisi Limonta, called a mistrial because he had not heard enough evidence to fairly decide the facts. The case was dismissed and ratified by the other members of the Court. Within 24 hours, Urquía Carreño approached the President of the First Chamber of the Supreme Court of Masonic Justice, Ernesto Valdés García (also the Secretary of the Board of Trustees at Llansó at the time of the theft) and demanded that the Supreme Court carry out a new trial. Outside of Freemasonry, Valdés García worked for Urquía Carreño's construction company (Spanish: mipyme), SME Edifica, SURL. The letters S-U-R-L, in this instance, are a Cuban business classifier which stands for Sociedad Unipersonal de Responsabilidad Limitada (English: Single-Member Limited Liability Company). Urquía Carreño pressured Valdés García to hold the trial or lose his job at the company, violating Masonic Law yet again, as the distinct separation of powers was codified into the bylaws of the Supreme Court of Masonic Justice when it was first created.
=== India === In India, after completing MBBS degree and one year of integrated internship, doctors can enroll in several types of postgraduate training programs: M.D. (DOCTOR OF MEDICINE) in: Anesthesiology, Anatomy, Biochemistry, Community Medicine, Dermatology Venereology and Leprosy, General Medicine, Forensic Medicine, Microbiology, Pathology, Paediatrics, Pharmacology, Physical medicine and rehabilitation, Physiology, Psychiatry, Radio diagnosis, Radiotherapy, Tropical Medicine, and, Tuberculosis & Respiratory Medicine. M.S. (MASTER OF SURGERY) in: Otorhinolaryngology, General Surgery, Ophthalmology, Orthopaedics, Obstetrics & Gynecology. D.M. (DOCTOR OF MEDICINE) in: Cardiology, Endocrinology, Medical Gastroenterology, Nephrology, and Neurology. M.Ch. (MASTER OF CHIRURGIE) in: Cardio vascular & Thoracic Surgery, Urology, Neurosurgery, Paediatric Surgery, Plastic Surgery. Or diploma in: Anesthesiology (D.A.), Clinical Pathology (D.C.P.), Dermatology Venereology and Leprosy (DDVL), Forensic Medicine (D.F.M.), Obstetrics & Gynaecology (D.G.O.), Ophthalmology (D.O.), Orthopedics (D.Ortho.), Otorhinolaryngology (D.L.O.), Paediatrics (D.C.H.) Psychiatry (D.P.M.), Public health (D.P.H.), Radio-diagnosis (D.M.R.D.), Radiotherapy (D.M.R.T.)., Tropical Medicine & Health (D.T.M. & H.), Tuberculosis & Chest Diseases (D.T.C.D.), Industrial Health (D.I.H.), Maternity & Child Welfare (D. M. C. W.)
=== 1995–2006: DNA identity testing === In 1995, Bio-Synthesis, Inc. introduced DNA identity testing to its broad range of molecular diagnostic services. Today, the DNA Identity Testing Center of BSI uses advanced techniques and automated systems to produce the most accurate DNA testing results allowed by current scientific technologies. The DNA Identity Testing Center has its own staff of scientific professionals whose focus is to ensure the quality and integrity of all tests and services. In 2000, Bio-Synthesis, Inc. perform the genetic analysis close to 500 Chinese nationals that were soliciting, under the right of abode, the right to move to Hong Kong by proving that their biological fathers were Hong Kong residents.
=== Hollow microneedles === Hollow MNs are designed with a hole at the tip and a hollow capacity that store drugs. Upon MNs insertion, the stored drug is directly injected into the dermis and this effectively facilitates the absorption of either large-molecular or large-dosage drug. Yet, a portion of the drug can leaked or become clogged, and may hinder the overall drug administration. Since the delivery of the drug depends on the flow rate of the microneedle, this type of array could become clogged by excessive swelling or flawed design. This design also increases the likelihood of buckling under the pressure and therefore failing to deliver any drugs.
Melanocytes and basal cells are embedded in the epidermal layer. Upon exposure to UVB rays, melanocytes will produce more melanin, a pigment that gives skin its color. UVB can cause the formation of freckles and dark spots, both of which are symptoms of photoaging; these are most common in people with fair or light skin. With frequent long-term exposure to UVB rays, signs of photoaging might appear, and precancerous lesions or skin cancer may develop as well as damage to DNA. UVA rays are able to penetrate deeper into the skin than UVB rays, damaging the dermal layer as well as the epidermal layer. The dermis is the second major layer of the skin, and it comprises collagen, elastin, and extrafibrillar matrix, which provides structural support to the skin. With chronic UVA exposure, damage to dermal collagen, elastin, and the extracellular matrix contributes to skin laxity, roughness, and wrinkling. Due to the presence of blood vessels in the dermis, UVA rays can lead to dilated or broken blood vessels, which are most commonly visible on the nose and cheeks. UVA can also damage DNA indirectly through the generation of reactive oxygen species (ROS), which include superoxide anion, peroxide, and singlet oxygen. These ROS damage cellular DNA as well as lipids and proteins.
Sources: en.wikipedia.org
=== Self-cleaning properties === In order to mimic the strong adhesion, easy detachment, and self-cleaning properties of a gecko toe pad, a fibrillar-based adhesive can be created. These performance features stem from the underlying hierarchical structure which consists of a million microfibrils called setae which further consists of billions of nano-sized branches called spatulae. Mimicking this phenomenon involves four distinct design steps:
Radium's long half-life of 1600 years means that surfaces coated with radium paint, such as watch faces and hands, remain a health hazard long after their useful life is over. There are still millions of luminous radium clock, watch, and compass faces and aircraft instrument dials owned by the public. The case of the "Radium Girls", workers in watch factories in the early 1920s who painted watch faces with radium paint and later contracted fatal cancer through ingesting radium when they pointed their brushes with their lips, increased public awareness of the hazards of radioluminescent materials, and radioactivity in general.
== Toxicity == Buformin was withdrawn from the market in many countries due to an elevated risk of causing lactic acidosis (although not the US, where it was never sold). Buformin is still available and prescribed in Romania (timed release Silubin Retard is sold by Zentiva), Hungary, Taiwan and Japan (sold by Nichi-Iko Pharmaceutical Co., Ltd as "DIBETOS" tablets, each containing 50 mg buformin hydrochloride). The lactic acidosis occurred only in patients with a buformin plasma level of greater than 0.60 μg/mL and was rare in patients with normal renal function. In one report, the toxic oral dose was 329 ± 30 mg/day in 24 patients who developed lactic acidosis on buformin. Another group of 24 patients on 258 ± 25 mg/day did not develop lactic acidosis on buformin.
In normal conditions, the human intestine absorbs mainly nonphosphorylated B6 vitamers. The phosphorylated forms of B6 and the glucoside of pyridoxine can be hydrolyzed by intestinal phosphatases and an intestinal glycosidase, respectively, to promote passive diffusion of pyridoxamine, pyridoxine and pyridoxal. In the liver or intestine, they are then rephosphorylated by pyridoxal kinase (EC 2.7.1.35) to avoid inverse diffusion A transport protein / membrane carrier of PLP (and other phosphorylated forms of B6) is the human membrane enzyme NAPE-PLD N-acyl phosphatidylethanolamine-specific phospholipase D of the endocannabinoid system. In the presence of bile acids (e.g., digestion), NAPE-PLD with its internal channel creates membrane-pores as dynamic conductive pathways through which the charged cofactors of vitamin B6 can diffuse through cell membranes and membranes of subcellular compartments (e.g., mitochondria, peroxisome, and endosome), where they exert the specific enzymatic activities. NAPE-PLD is thus functional to the intracellular uptake and mobilization of PLP, and to the increased demand of the cofactor in pathological conditions having a higher endocannabinoid tone. Intracellular-free PLP concentrations are maintained at approximately 1 μM to prevent inappropriate reactions. Proteins that bind PLP and help maintain low-free PLP concentrations include glycogen phosphorylase in muscle, hemoglobin in erythrocytes, albumin in plasma, and NAPE-PLD mainly in the brain, gut, liver, kidney and reproductive system.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.